

TABLE S1: Adverse events

Summary of adverse events	Control Fluid	Citrate Fluid	Wash out
Total Adverse events	18	16	5
<i>General disorders</i>	3	2	4
<i>Infections and infestations</i>	3	8	1
<i>Investigations</i>	2	0	0
<i>Metabolism and nutrition disorders</i>	3	0	0
<i>Others</i>	7	6	0
Total serious adverse events (n)	5	3	2
Total product related adverse events (n)	0	3*	1**

* Classified as not assessable in relationship to study product by investigator but worst-case assessed by sponsor

** Patient accidentally received study product during wash-out

TABLE S2: Biocompatibility parameters (pre-dialysis)

Parameter, Mean \pm SEM	Control Fluid		Citrate Fluid	
	Week 0	Week 6	Week 0	Week 6
Inflammation				
<i>CRP (mg/l)</i>	17.5 \pm 8.9	8.4 \pm 2.1	8.3 \pm 3.6	13.8 \pm 0.34
<i>Pentraxin 3 (ng/ml)</i>	1.76 \pm 0.29	1.90 \pm 0.30	1.82 \pm 0.39	2.01 \pm 0.34
<i>IL-6 (ng/l)</i>	17.3 \pm 8.2	11.4 \pm 1.7	11.9 \pm 2.3	13.6 \pm 3.0
<i>TNF-α (ng/l)</i>	26.3 \pm 1.3	24.9 \pm 1.5	26.3 \pm 1.4	25.5 \pm 1.4
Oxidative stress				
<i>MDA (μM)</i>	1.64 \pm 0.15	1.55 \pm 0.15	1.59 \pm 0.14	1.57 \pm 0.14
<i>8-oxo-dG (ng/ml)</i>	0.59 \pm 0.04	0.62 \pm 0.04	0.61 \pm 0.04	0.65 \pm 0.04
<i>mAOPP (μM)</i>	118.0 \pm 6.2	109.1 \pm 4.6	108.6 \pm 5.1	106.9 \pm 4.0
<i>Glutathione GSH/GSSG ratio</i>	0.28 \pm 0.04	0.28 \pm 0.04	0.32 \pm 0.04	0.25 \pm 0.03
<i>γGluCys (μM)</i>	3.10 \pm 0.16	3.08 \pm 0.16	3.21 \pm 0.18	3.01 \pm 0.16
<i>CysGly (μM)</i>	57.3 \pm 3.4	58.2 \pm 3.4	57.2 \pm 3.4	55.6 \pm 3.0
<i>Cys (μM)</i>	428 \pm 22	446 \pm 21	446 \pm 23	424 \pm 20
<i>HomoCys (μM)</i>	22.5 \pm 2.1	21.2 \pm 1.3	22.5 \pm 1.7	21.1 \pm 1.4
Advanced Glycation End-products				
<i>Total AGE (AU)</i>	6456 \pm 365	6280 \pm 326	6935 \pm 826	6466 \pm 293
<i>CML (ng/ml)</i>	122 \pm 9.8	116 \pm 10.2	119 \pm 9.6	118 \pm 10.1
<i>Pentosidine (nM)</i>	1489 \pm 154	1507 \pm 149	1468 \pm 144	1490 \pm 138